Abbisko Cayman (HKG:2256) forecasts it will turn to a profit of 10 million yuan in 2024 from a loss of 432 million yuan in the year-ago period, according to a Monday filing with the Hong Kong Exchange.
Revenue is also seen to surge to 504 million yuan in 2024 from 19 million yuan in 2023, the filing said.
The rise is attributable to better cost control and efficiency, as well as an upfront payment of $70 million from the out-licensing agreement with Merck for pimicotinib, the filing said.
Shares surged 5% during Monday's morning trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。